Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
GLOW 70mg
70mg
Related Research News
Retatrutide 30mg: Triple Agonist for Metabolic Research
Retatrutide 30mg, developed by Eli Lilly, acts as a triple agonist targeting GLP-1, GIP, and glucagon receptors to study weight regulation and energy balance. Research highlights its role in appetite control, glucose management, energy expenditure, and fat oxidation. Lab testing shows average purity of 99.93% and mass of 35.05 mg from Freedom Diagnostics on 2026-04-24, lot LY-3437943.
Oral Semaglutide Delivers 21.6% Weight Loss in Early Responders, 77.3% Mobility Gains
In the OASIS 4 trial, oral semaglutide 25 mg led to 21.6% weight loss among early responders, who made up 28.8% of participants with at least 10% loss by week 16. Those not meeting that mark, nearly three-quarters, still achieved 11.5% weight loss by week 64. Participants with poor baseline physical function saw 77.3% achieve meaningful improvements versus 42.9% on placebo.
Magnesium Bisglycinate: Muscle Recovery and Relaxation Aid
Magnesium bisglycinate offers a highly absorbable form of magnesium that supports muscle function, post-exercise recovery, and relaxation without common stomach issues. Each serving provides 200 mg in unflavored capsules. It aids energy production, bone health, and electrolyte balance for active individuals.